Lindsey Shapiro, PhD,  science writer—

NeuroOne Medical Technologies‘ Evo stereoelectroencephalography (sEEG) electrodes for measuring or stimulating brain activity in people with neurological diseases like Parkinson’s disease or epilepsy are now available commercially in the U.S. The electrodes were approved by the U.S. Food and Drug Administration (FDA) in October for less than…

People newly diagnosed with Parkinson’s disease were found to have significantly lower blood levels of the argonaute 2 (AGO2) protein relative to healthy adults, according to a recent biomarker study conducted by NeuroSense Therapeutics. In people with amyotrophic lateral sclerosis (ALS), the company’s PrimeC treatment candidate previously…

IPX203, Amneal Pharmaceuticals‘ investigational extended-release carbidopa/levodopa (CD/LD) treatment for Parkinson’s disease, continued to exhibit a favorable safety and efficacy profile during the open-label extension part of the Phase 3 RISE-PD trial. “IPX203 remained as efficacious and safe as it was shown during the RISE-PD study, and the vast…

Parkinson’s disease patients treated with prasinezumab for three years — as part of a long-term extension of the Phase 2 PASADENA clinical trial — were shown to be at a lower risk of motor symptom progression and motor complications than patients who started treatment a year later, according to…

Physiotherapy, and mind-body exercise particularly, can meaningfully ease motor symptoms of Parkinson’s disease, a recent meta-analysis of clinical trial data involving more than 2,500 people reported. Mind-body exercise refers to practices that focus on the connection between the body, breath, and the mind, such as yoga, tai chi, or…

Medications to prevent nausea and vomiting usually are not necessary for Parkinson’s disease patients beginning treatment with Kynmobi (apomorphine hydrochloride), according to a recent analysis of Phase 3 clinical trial data. Nearly 90% of patients who did not use these medications were still able to achieve an optimal…

Changes in the electrical activity of a brain region called the left inferior frontal cortex (LIFC) may underlie certain speech difficulties in people with Parkinson’s disease, a study found. Patients with more severe articulation problems had higher frequency activity in the LIFC, and more limited communication between the LIFC…

A molecule associated with oxidative stress, called allantoin, is found at higher levels in the blood of people with Parkinson’s disease relative to their peers without the neurodegenerative disorder, according to a new study. Allantoin and its ratio to uric acid (UA) — the antioxidant molecule from which it’s…

Black, Hispanic, and Asian people with Parkinson’s disease report lower health-related quality of life (HRQoL) than their white counterparts, a recent study showed. Differences in cognitive performance were found to partly underlie these disparities. The study, “Racial and Ethnic Differences in Health-Related Quality of Life for Individuals with…

A higher neutrophil-to-lymphocyte ratio and low lymphocyte counts in the bloodstream, thought to reflect greater systemic inflammation, were associated with fewer dopamine-producing nerve cells in the brains of Parkinson’s disease patients, a study showed. These immune alterations were also generally linked to worse motor function across both groups. The…